Tamiflu oseltamivir phosphate market?

Do you want a global overview or for a specific country/region and year? Here’s a quick snapshot, then I can tailor with numbers.

What Tamiflu is
- Tamiflu is the brand name for oseltamivir phosphate, a oral neuraminidase inhibitor used to treat uncomplicated influenza A/B in adults and children and to reduce the risk of flu in exposed individuals.
- It’s typically prescribed for symptoms that started within the last 48 hours.

Market landscape (high-level)
- Leading antiviral for influenza for many years, with Tamiflu (oseltamivir) accounting for a large share of outpatient influenza antiviral prescriptions.
- Generics and competition: In many markets, generic oseltamivir products are available, which affects price and share. Other influenza antivirals on the market include baloxavir marboxil (Xofluza), zanamivir (Relenza), and peramivir (Rapivab). Baloxavir, introduced in the late 2010s, offers a single-dose regimen and has captured some market share, particularly where it’s available and reimbursed.
- Market drivers: yearly influenza activity, public health guidelines, influenza pandemics (which tend to spike antiviral use), and pricing/reimbursement policies. Supply and access can be influenced by manufacturing capacity and stockpiling practices in different regions.
- IP and competition: Patent expiry and entry of generics vary by country. In many major markets, generic oseltamivir has reduced the price pressure on Tamiflu, while Roche continues to market Tamiflu as the branded option in addition to generic versions.

What I can give you next
- If you specify a country/region and a year (e.g., global in 2023, US market 2020–2022, EU market 2021, etc.), I can pull together:
- approximate market size and growth
- market share of Tamiflu vs. competitors
- number of players (brand vs. generics)
- key price/reimbursement dynamics
- any notable regulatory or supply issues

Would you like global figures or data for a specific market and timeframe?